Your email has been successfully added to our mailing list.

×
0.00282485875706221 -0.00423728813559326 -0.00282485875706209 0.00847457627118651 -0.0607344632768361 -0.0784745762711865 -0.0734463276836158 -0.0967796610169492
Stock impact report

Progenics Pharmaceuticals +21% on NDA acceptance [Seeking Alpha]

PROGENICS PHARMACEUTICALS (PGNX) 
Last progenics pharmaceuticals earnings: 8/9 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: progenics.com
Company Research Source: Seeking Alpha
Progenics Pharmaceuticals +21% on NDA acceptanceProgenics Pharmaceuticals (NASDAQ:PGNX)announces that the FDA has accepted for review its New Drug Application for rare neuroendocrine tumor treatment Azedra.The FDA also granted the request for priority review and set the PDUFA date for April 30.Progenics shares areup 20.5% premarket.See all stocks on the move »Now read:Progenics Pharmaceuticals (PGNX) Presents At Jefferies 2017 London Healthcare Conference - Slideshow » Show less Read more
Impact Snapshot
Event Time:
PGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for PGNX alerts
Opt-in for
PGNX alerts

from News Quantified
Opt-in for
PGNX alerts

from News Quantified